With COVID-19, questions about how infections cause lasting immunity, or don’t, and how you know and what it all means for vaccines have become a matter of public focus. But some immunologists have been pondering those questions for years. “The immune system has a very good memory,” Bali Pulendran told BioWorld. “Clearly, some viruses and some pathogens can enter the body and stimulate the immune system, and the immune system can remember that encounter for decades.”
Keeping you up to date on recent developments in diagnostics, including: A.I. tool promises faster, more accurate Alzheimer's diagnosis; Bioluminescent tool tracks DNA break repair; Mechanisms of retinopathy come into focus.
Keeping you up to date on recent developments in oncology, including: Microspheres paired with LHRH perform well in study of triple-negative breast cancer; New partner in crime for AHR; MMA induces epithelial-to-mesenchymal transition; SCCA incidence trending up in U.S.
Through the use of sequencing data, researchers in Hong Kong presented a case study providing the strongest evidence yet that individuals can become reinfected with SARS-CoV-2 after clearing a first infection.
Keeping you up to date on recent developments in neurology, including: Novasignal’s Lucid robotic system reveals insights into COVID-19; Sensing eye mask developed to improve data capture in neuro studies; Multiple sclerosis’ early days; How antidepressants inhibit fibrosis.
BioWorld looks at translational medicine, including: Mechanisms of retinopathy come into focus; New partner in crime for AHR; Multiple sclerosis’ early days; MMA induces EMT; CAR T cells for inhibition; Islet organoids can evade immune attack, Cross-reactive immunity helps antitumor response; How antidepressants inhibit fibrosis; Just add fever.
Keeping you up to date on recent developments in diagnostics, including: Antigen test detects spike proteins of SARS-CoV-2; Blood volume assessment study to use Daxor device; Gaining insights into loss of function.
Stimulator of interferon genes (STING) is a protein that senses DNA in the cytosol, where it comes from either an infectious invader or a damaged nucleus and sets off an immune response that ultimately results in the activation of T cells. STING agonists are among the strategies that have been tested in hopes they would increase the response rate to checkpoint blockade. Now, back-to-back papers in the Aug. 21, 2020, issue of Science have detailed the preclinical development of orally available STING agonists.
